.Attributes Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medication conjugate (ADC) tisotumab vedotin resulted in improved progression-free as well as overall survival, triggering FDA approval as well as a new treatment alternative for clients.